<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05079789</url>
  </required_header>
  <id_info>
    <org_study_id>AmiloridNS-01</org_study_id>
    <secondary_id>2019-002607-18</secondary_id>
    <nct_id>NCT05079789</nct_id>
  </id_info>
  <brief_title>Amiloride in Nephrotic Syndrome</brief_title>
  <acronym>AMILOR</acronym>
  <official_title>Randomized, Controlled Interventional Trial to Investigate the Efficacy of Amiloride for the Treatment of Edema in Human Nephrotic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The AMILOR study compares treatment of edema in nephrotic syndrome with Amiloride vs.&#xD;
      Furosemide.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The monocenter randomized-controlled AMILOR trial investigates the efficacy of the ENaC&#xD;
      blocker amiloride in reducing edema in nephrotic syndrome compared with standard therapy with&#xD;
      the loop diuretic furosemide.&#xD;
&#xD;
      Patients with acute nephrotic syndrome are randomized to receive amiloride (starting dose 5&#xD;
      mg) or furosemide (starting dose 40 mg) for 16 days. The target number of patients is n = 18&#xD;
      per arm. Exclusion criteria include GFR &lt;30ml/min/1.73m², AKIN 1 and 2, hypotension, hyper-/&#xD;
      hypokalemia, and hyponatremia. Overhydration is quantified by bioimpedance spectroscopy.&#xD;
      Depending on the course of overhydration, dose adjustments (day 2, 5, 8, 12) or addition of&#xD;
      HCT (day 8) are performed during the course of the study.&#xD;
&#xD;
      Primary endpoint is decrease in overhydration at day 8, secondary endpoints include decrease&#xD;
      in overhydration at day 16, as well as body weight, edema volume, blood pressure, urine&#xD;
      volume, natriuresis at day 8 and 16, and need for dose adjustments and co-medication with&#xD;
      HCT. Plasma potassium, sodium, and creatinine concentrations are measured as safety&#xD;
      parameters.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 8, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 8, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease of overhydration</measure>
    <time_frame>8 days</time_frame>
    <description>Decrease of overhydration (OH) measured by bioimpedance spectroscopy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decrease of overhydration</measure>
    <time_frame>16 days</time_frame>
    <description>Decrease of overhydration (OH) measured by bioimpedance spectroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease of body weight</measure>
    <time_frame>8 and 16 days</time_frame>
    <description>Decrease of body weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease of edema cercumference</measure>
    <time_frame>8 and 16 days</time_frame>
    <description>Decrease of edema cercumference, measured at the lower leg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease of blood pressure</measure>
    <time_frame>8 and 16 days</time_frame>
    <description>Decrease of systolic and diastolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increase of urine volume and natriuresis</measure>
    <time_frame>8 and 16 days</time_frame>
    <description>Increase of urine volume and natriuresis, measured in 24 hours collected urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Course of plasma renin activity and serum aldosterone concentration</measure>
    <time_frame>8 and 16 days</time_frame>
    <description>Course of plasma renin activity and serum aldosterone concentration, measured in blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of dose of study medication and need for co-medication</measure>
    <time_frame>8 and 16 days</time_frame>
    <description>Number of required changes of dose of study medication and need for co-medication with HCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adverse events</measure>
    <time_frame>16 days</time_frame>
    <description>Occurrence of adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Nephrotic Syndrome</condition>
  <condition>Edema</condition>
  <condition>Sodium Retention</condition>
  <arm_group>
    <arm_group_label>Amiloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment wirh Amiloride, start dose 5 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Furosemide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment with Furosemide, start dose 40 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amiloride</intervention_name>
    <description>Treatment with amiloride, start dose 5 mg</description>
    <arm_group_label>Amiloride</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Furosemide</intervention_name>
    <description>Treatment with furosemide, start dose 40 mg</description>
    <arm_group_label>Furosemide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Acute nephrotic syndrome with proteinuria &gt; 3 g/day and formation of edema.&#xD;
&#xD;
          2. Age ≥ 18 years at the time of signing the informed consent.&#xD;
&#xD;
          3. Understand and voluntarily sign an informed consent document prior to any study&#xD;
             related assessments/procedures.&#xD;
&#xD;
          4. Ability to adhere to the study visit schedule and other protocol requirements.&#xD;
&#xD;
          5. Use of adequate thrombosis prophylaxis due to the increased risk of thrombosis in&#xD;
             nephrotic syndrome and the expected fluctuations in volume balance during study&#xD;
             participation.&#xD;
&#xD;
          6. Subject (male or female) is willing to use highly effective methods of contraception&#xD;
             according to the &quot;Clinical trial fertility group&quot; recommendations.&#xD;
&#xD;
          7. Female Patients of childbearing potential (WOCBP) must agree to pregnancy testing&#xD;
             before inclusion in the study.&#xD;
&#xD;
          8. Female Patients must agree to abstain from breastfeeding during study participation&#xD;
             and 28 days after study drug discontinuation.&#xD;
&#xD;
          9. All subjects must agree not to share medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Severe reduction of kidney function: Creatinine clearance or calculated GFR &lt; 30&#xD;
             mL/min/1.73m² or acute kidney injury KDIGO stage 2 or 3 or anuria.&#xD;
&#xD;
          2. Hypovolemia or dehydration.&#xD;
&#xD;
          3. Uncontrolled diabetes mellitus.&#xD;
&#xD;
          4. Hypotension, systolic blood pressure &lt; 90 mmHg.&#xD;
&#xD;
          5. Hyperkalemia, plasma potassium concentration &gt; 4.8 mmol/l.&#xD;
&#xD;
          6. Hypokalemia, plasma potassium concentration &lt; 3.3 mmol/l.&#xD;
&#xD;
          7. Hyponatremia, plasma sodium concentration &lt; 128 mmol/l.&#xD;
&#xD;
          8. Hypercalcemia, ionized calcium &gt; 2.0 mmol/l or total albumin corrected calcium &gt; 3.0&#xD;
             mmol/l.&#xD;
&#xD;
          9. Signs of cardiac decompensation (orthopnoe, dyspnoe NYHA IV).&#xD;
&#xD;
         10. Hepatic coma or precoma.&#xD;
&#xD;
         11. Symptoms of gout.&#xD;
&#xD;
         12. Current therapy with potassium-sparing diuretics (e.g. spironolactone) or potassium&#xD;
             supplements.&#xD;
&#xD;
         13. Women during pregnancy and lactation.&#xD;
&#xD;
         14. History of hypersensitivity to the investigational medicinal product, comparator or&#xD;
             co-medication or to any drug with similar chemical structure or to any excipient&#xD;
             present in the pharmaceutical form of the investigational medicinal product,&#xD;
             comparator or co-medication.&#xD;
&#xD;
         15. Any other clinical condition that would jeopardize the patient's safety while&#xD;
             participating in this clinical trial.&#xD;
&#xD;
         16. Active participation in other clinical trials or observation period of competing&#xD;
             trials.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ferruh Artunc, Prof., MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Tuebingen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anja Schork, MD</last_name>
    <phone>+49 7071 2982712</phone>
    <email>Anja.Schork@med.uni-tuebingen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ferruh Artunc, Prof., MD</last_name>
    <phone>+49 7071 2982712</phone>
    <email>Ferruh.Artunc@med.uni-tuebingen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <state>Baden-Wuerttemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anja Schork, MD</last_name>
      <phone>+49 7071 2982712</phone>
      <email>Anja.Schork@med.uni-tuebingen.de</email>
    </contact>
    <contact_backup>
      <last_name>Ferruh Artunc, Prof., MD</last_name>
      <phone>+49 7071 2982712</phone>
      <email>Ferruh.Artunc@med.uni-tuebingen.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.medizin.uni-tuebingen.de/de/das-klinikum/einrichtungen/kliniken/medizinische-klinik/innere-medizin-iv/forschung/nierenphysiologie</url>
    <description>Homepage working group Prof. Artunc</description>
  </link>
  <reference>
    <citation>Artunc F, Wörn M, Schork A, Bohnert BN. Proteasuria-The impact of active urinary proteases on sodium retention in nephrotic syndrome. Acta Physiol (Oxf). 2019 Apr;225(4):e13249. doi: 10.1111/apha.13249. Epub 2019 Jan 18. Review.</citation>
    <PMID>30597733</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 2, 2021</study_first_submitted>
  <study_first_submitted_qc>October 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2021</study_first_posted>
  <last_update_submitted>October 2, 2021</last_update_submitted>
  <last_update_submitted_qc>October 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Tuebingen</investigator_affiliation>
    <investigator_full_name>Dr. Anja Schork</investigator_full_name>
    <investigator_title>Clinincal Investigator, Project management</investigator_title>
  </responsible_party>
  <keyword>Nephrotic Syndrome</keyword>
  <keyword>ENaC</keyword>
  <keyword>Diuretic therapy</keyword>
  <keyword>Amiloride</keyword>
  <keyword>Proteasuria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephrotic Syndrome</mesh_term>
    <mesh_term>Nephrosis</mesh_term>
    <mesh_term>Hypernatremia</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amiloride</mesh_term>
    <mesh_term>Furosemide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

